A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 331-335

  Motta, J O C ^a   Sampaio, R N R ^a,b  

^a HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE; MEGLUMINE ANTIMONATE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEG ULCER; LEISHMANIASIS; LOW DRUG DOSE; MALE; MYALGIA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SKIN LEISHMANIASIS; TACHYCARDIA; TREATMENT OUTCOME; ULCER HEALING; UNITED STATES;

ADULT; AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84857350892     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04070.x     Document Type: Article

References (27)

1. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnosis and therapeutics. Clin Exp Dermatol 2010; 35: 669-705.
2. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-596. (Pubitemid 47277438)
3. Del Rosal T, Artigao FB, Miguel MJ, et al. Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr 2010; 56: 122-124.
4. Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in travelers. J Travel Med 2009; 16: 123-131.
5. Mitropoulos P, Kouidas P, DurKin-Kouidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010; 63: 309-322.
6. Ashutosh K, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in leishmania. J Med Microbiol 2007; 56: 143-153.
7. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with Miltefosine. Trans R Soc Trop Med Hyg 2006; 100: 34-40.
8. Devlin RK, Parsonnet J, Klaus SN. Treatment of relapsed cutaneous Leishmania (Viannia) braziliensis infection with liposomal amphotericin B. Infect Dis Clin Pract 2005; 13: 84-86. (Pubitemid 40344230)
9. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: Past, present and future. Cur med Chem 2007; 14: 1153-1169. (Pubitemid 46679457)
10. Filippin FB, Souza LC. Therapeutic efficacy of amphotericin B lipid formulations. Rev Bras Cienc Farm 2006; 42: 167-194.
11. Davidson RN, Di Martino L, Gradoni L. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75-81. (Pubitemid 24044213)
12. Davidson RN, Di Martini L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Diseases 1996; 22: 938-943. (Pubitemid 26260592)
13. Castagnola E, Davidson RN, Tasso PFL, et al. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1996; 90: 317-318. (Pubitemid 26188889)
14. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-findind study. Trans R Soc Trop Med Hyg 1996; 90: 319-322. (Pubitemid 26188890)
15. Freire M, Badarõ F, Avelar ME, et al. Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis 1997; 1: 230-240.
16. Di Martino L, Davidson RN, Giacchino R. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131: 271-277. (Pubitemid 27495249)
17. Sundar S, Agrawal G, Madhukar R, et al. Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomized trial. Brit Med J 2001; 323: 419-422. (Pubitemid 32801392)
18. Brown M, Noursadeghi M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of leishmania braziliensis cutaneous leishmaniasis. Brit J Dermatol 2005; 153: 203-205. (Pubitemid 41044552)
19. Torre-Cisneros J, Prada JL, Villanueva JL, et al. Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. Clin Infect Dis 1994; 18: 1024-1025. (Pubitemid 24171369)
20. Sampaio RNR, Marsden PD. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg 1997; 91: 77. (Pubitemid 27095508)
21. Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41: 752-756. (Pubitemid 27150525)
22. Amato VS, Nicodemo AC, Amato JG, et al. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B. J Antimicrob Chemother 2000; 46: 341-342. (Pubitemid 30639320)
23. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56: 612-616. (Pubitemid 46400168)
24. Hanham CA, Zhao FS, Shaw JJ, Lainson R. Monoclonal antibodies for the identification of New World Leishmania. Trans R Soc Trop Med Hyg 1991; 85: 220-226.
25. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J Global Infec Dis 2010; 2: 159-166.
26. Rodrigues AM, Hueb M, Rodrigues-Dos-Santos TAR, Fontes CJF. Factors associated with the treatment failure of cutaneous leishmaniasis with meglumine antimoniate. Rev Soc Bras Med Trop 2006; 39: 139-145. (Pubitemid 43735880)
27. Deps PD, Viana MC, Falqueto A, Dietze R. Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP 88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev Soc Bras Med Trop 2000; 33: 535-543. (Pubitemid 32108388)